1st EAB Meeting. The first External Advisory Board Meeting was organized at 23rd of April 2012 and participated all the SEEDRUG UPAT’s Consortium members and their teams,
Prof Ivano Bertini (Chair of the EAB) could not join the meeting due to health problems and was replaced by Prof Claudio Luchinat.
Industrial partners of the SEEDRUG project, members of the SME CBL Biopharmaceuticals Patras, (Prof K. Barlos & Prof D. Gatos) and spin-off company ELDRUG SA (Dr. Minos Matsoukas) with oral presentations and/or by taking part at the Round Table discussion.
UPAT’s authorities and Chairman of the Department of Pharmacy welcome addresses the participants.
SEEDRUG Coordinator opened the scientific part of the meeting and presented the work performed in each one of the SEEDRUG’s work packages already and the activity planned for the future (recruitment of the experienced researchers, progress on the research equipment acquisition, planned twinning & networking activities and dissemination activities).
All SEEDRUG consortium members provided an overview of their research plans through SEEDRUG project.
The members of the EAB commented on the progress made during the first 4 months of the project’s duration and on the future project’s plans. Specifically discussion included the following topics:
Industrial SEEDRUG partners (CBL Biopharmaceutical Patras, & ELDRUG SA) participated in the meeting suggesting means and actions towards the establishment of new links between SEEDRUG and industrial partners (through service and preparation of new products).
MONDAY 23rd APRIL 2012 | |
Conference & Cultural Center | |
Chairpersons | Z. Lygerou (Dept of Medicine) & I. Margiolaki (Dept of Biology) |
09:30 – 9:45 | Welcome Addresses - Introduction (The SEE-DRUG project) University of Patras Authorities & Georgios A. Spyroulias |
09:45 – 10:15 | Genomic Databases & personalized medicine |
10:15 – 10:50 | Pharmacological control of arterial smooth muscle and endothelial cell phenotype |
10:50 – 11:10 | EAB Member contribution |
Arkadia a RING domain E3 ubiquitin ligase, supports the tumor suppressing properties of the TGFbeta pathway | |
11:10 – 11:45 | NMR-based Structure-Activity Correlation Study of Arkadia E3 Ubiquitin Ligase Domain |
11:45 – 12:00 | Coffee Break |
Chairpersons | G.A. Spyroulias (Dept of Pharmacy) & K. Poulas (Dept of Pharmacy) |
12:00 – 12:45 | EAB Member contribution |
Lightening from NMR in Life Sciences | |
12:45 – 13:20 | SME Member contribution |
Studies on the “in vitro oxidative folding” of the A and B chains of the Insulin Like Peptides (INSL) | |
13:20 – 13:40 | Factors that modulate the pKa of the attacking thiolate anion of glutaredoxin |
13:40 – 14:00 | Discussion |
SEE-DRUG strategic plan – Suggestions & Comments by EAB members | |
14:00 – 15:30 | Light lunch & Coffee |
Chairpersons | T. Tselios (Dept of Chemistry) & A. Vlamis (Dept of Chemistry) |
15:30 – 16:15 | EAB Member contribution |
The curious story of J-base and JBP1. | |
16:15 – 16:50 | Control of DNA replication in time and space |
16:50 – 17:10 | Peptide-mimetics, a new generation of drugs |
17:10 – 17:30 | Closing Remarks |